DAYBREAK Study Confirms Zeposia's Sustained Efficacy and Safety in RMS Patients

Bristol Myers Squibb has reported new findings from the Phase 3 DAYBREAK trial, which highlight the enduring effectiveness and safety of Zeposia (ozanimod) in treating patients with multiple sclerosis (MS). The study showed a low annualized relapse rate of 0.098 and noted that 67% of patients remained relapse-free after six years of treatment. The drug's safety profile was found to be consistent with previous studies, with nearly a decade of clinical experience backing it.
In an additional analysis from DAYBREAK, it was observed that 97% of patients who stopped taking Zeposia were relapse-free 90 days after discontinuation. Those who did experience a relapse showed no signs of a rebound effect. The data from the trial, which included 2,494 participants exposed to Zeposia for an average of 60.9 months, revealed no new safety concerns. The most frequently reported adverse events were nasopharyngitis, headache, COVID-19 infection, and upper respiratory tract infection.
The study's results reinforce Zeposia's position as a significant treatment option for MS, emphasizing its sustained efficacy and safety. The findings were set to be presented at the 9th annual ACTRIMS Forum in Florida, along with other research abstracts that further the understanding of Zeposia's role in treating MS.
Zeposia is an oral medication that modulates the sphingosine 1-phosphate (S1P) receptor, reducing the migration of lymphocytes into the central nervous system, which may contribute to its therapeutic effects in MS. The drug is approved globally for use in adults with relapsing forms of MS and ulcerative colitis.
Multiple sclerosis is a disease where the immune system attacks the nerve's protective covering, disrupting communication between the brain and the body, potentially leading to nerve degeneration. MS affects millions of people worldwide, with relapsing forms being the most common at the time of diagnosis.
Bristol Myers Squibb is dedicated to advancing neuroscience through the development of potential medicines for neurological disorders, aiming to improve patient outcomes by targeting key pathways involved in disease initiation and progression. The company's commitment to innovation in neuroscience is evident in its ongoing research and development efforts within this field.